Cold type haemolytic anaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 14 Aug 2026 04:04:11 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.4 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cold type haemolytic anaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of cc-97540 CD19‑Targeted NEX‑T CAR T in participants with chronic immune thrombocytopenia and autoimmune hemolytic anemia https://clinicaltrials.eu/trial/study-of-cc-97540-cd19-targeted-nex-t-car-t-in-participants-with-chronic-immune-thrombocytopenia-and-autoimmune-hemolytic-anemia/ Wed, 12 Aug 2026 04:13:50 +0000 https://clinicaltrials.eu/trial/study-of-cc-97540-cd19-targeted-nex-t-car-t-in-participants-with-chronic-immune-thrombocytopenia-and-autoimmune-hemolytic-anemia/ The study focuses on two blood‑cell disorders: Chronic Immune Thrombocytopenia (cITP), in which the body destroys platelets that help stop bleeding, and Autoimmune Hemolytic Anemia (AIHA), where the immune system attacks red blood cells, leading to anemia. The investigational therapy is a specially engineered cell product called Zolacabtagene Autoleucel (BMS-986353), also known as Zola‑cel, which belongs to a class of treatments named CD19-Targeted NEX‑T CAR T Cells. These cells are made from a patient’s own immune cells, altered in the laboratory, and then given back through an intravenous (through the vein) infusion; the active ingredient is identified by the code cc-97540. The main goal of the trial is to see whether this therapy is safe, tolerable, and effective in improving blood counts for people with these conditions.

Participants will first undergo screening tests, then receive a single infusion of the modified cells. After the infusion, they will have regular clinic visits where blood samples are drawn and simple health questionnaires are completed to monitor for any side effects and to check if platelet or red‑cell numbers improve. Follow‑up continues for several months to observe how long any benefit lasts and to record any additional medical support needed. Throughout the study, doctors will watch for any unusual lab results or symptoms and will provide standard medical care as needed.

]]> Study on Zanubrutinib for Patients with Primary Cold Agglutinin Disease https://clinicaltrials.eu/trial/study-on-zanubrutinib-for-patients-with-primary-cold-agglutinin-disease/ Mon, 03 Aug 2026 10:24:07 +0000 https://clinicaltrials.eu/trial/study-on-zanubrutinib-for-patients-with-primary-cold-agglutinin-disease/ This clinical trial is focused on studying a condition known as Cold Agglutinin Disease (CAD). CAD is a rare blood disorder where the immune system mistakenly attacks and destroys red blood cells, especially in cold temperatures. The trial will investigate the effects of a medication called Zanubrutinib, which is a type of drug known as a tyrosine kinase inhibitor. This medication is taken orally in the form of a capsule.

The purpose of the study is to evaluate how effective Zanubrutinib is in treating patients with primary CAD. Participants in the study will receive Zanubrutinib over a series of 6 treatment cycles. During these cycles, the response of the disease to the medication will be closely monitored. The study aims to see if Zanubrutinib can help reduce the symptoms of CAD and improve the overall health of the participants.

Throughout the study, various aspects of the participants’ health will be assessed, including changes in blood parameters and symptoms related to CAD. The study will also look at how the treatment affects the quality of life and fatigue levels of the participants. The trial is designed to provide valuable information on the potential benefits of Zanubrutinib for individuals living with CAD.

]]> Study on Povetacicept for Patients with Autoimmune Cytopenias (wAIHA, CAD, ITP) https://clinicaltrials.eu/trial/study-on-povetacicept-for-patients-with-autoimmune-cytopenias-waiha-cad-itp/ Mon, 03 Aug 2026 10:24:07 +0000 https://clinicaltrials.eu/trial/study-on-povetacicept-for-patients-with-autoimmune-cytopenias-waiha-cad-itp/ This clinical trial is focused on studying autoimmune cytopenias, which are conditions where the immune system mistakenly attacks and destroys blood cells. The specific types of autoimmune cytopenias being studied include warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), and immune thrombocytopenia (ITP). The treatment being tested in this study is called Povetacicept Injection, also known by its code name ALPN-303. This medication is given as a solution for injection under the skin.

The purpose of the study is to evaluate the safety and tolerability of Povetacicept in individuals with these autoimmune conditions. Participants in the study will receive Povetacicept and will be monitored to assess how their bodies respond to the treatment. The study will look at various factors, including any side effects that may occur and how the medication affects the participants’ health over time.

Throughout the study, participants will receive regular check-ups and assessments to ensure their well-being and to gather information on the effectiveness of the treatment. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. This trial aims to provide valuable insights into the potential benefits and risks of using Povetacicept for treating autoimmune cytopenias.

]]>